【摘 要】
：
--An introduction to a catalog of 30,000 plus novel building blocks, which are designed by analysis of the structures of a large number of real marketed and
【出 处】
：
亚太药物研发领袖峰会(Asia Pharma R&D Leaders Summit 2018)
论文部分内容阅读
--An introduction to a catalog of 30,000 plus novel building blocks, which are designed by analysis of the structures of a large number of real marketed and investigational medicines, as well as findings reported in most current literature in medicinal chemistry.--How these building blocks can accelerate the exploration of structure-activity and structure-property relationships in drug discovery.Real cases on solving issues like hERG, improving metabolic stability,increasing solubility, and extending potential patent space, will be discussed.
其他文献
Outline · Trends in globalization of clinical drug development and ethnicity focused regulatory environment · Mechanisms for ethnic differences in drug respon
Content 1.Use of PPK, PK/PD in clinical research of antimicrobial agents 2.PPK and PK/PD guide optimization of treatment regimen 3.PPK and PK/PD guide treatment
·Drug development decision makers need In rely on robust rationale to select drug candidates, targets, trial designs, dose regimens, patient populations and su
Cancer therapy PD of Irreversible Effects: Phase-nonspecific PD of Irreversible Effects: Phase-nonspecific PD of Irreversible Effects: Cell-cycle Specific
BIODURO The Spring is here! The Spring of Drug Discovery in China is here Talents Policy Money Entrepreneurship Basic research
致谢中国外商投资企业协会药品研制和开发行业委员会(RDPAC)的成员-默沙东中国有限公司,Wendy Yu-罗氏(中国)控股有限公司,Melly Lin
Were developing treatments for cancer Why worry about rare cardiac side effects?
乌克兰国家药典的地位:根据药品法乌克兰国家药典是一部法案.药典的要求对生产,贮藏,分发和使用药品的所有乌克兰企业和院校具有强制性,不管他们的所有权如何.
Background Stem Cell Based Technologies have become a Therapeutic Strategy Cellular Replacement & Repair Biomaterials & Organ Regeneration Immunology and Micro-
OBJECTIVES Primary: Maximum Tolerated Dose (MTD) and Recommended Dose (RD).Secondary: Safety, Tolerability and Pharmacokinetics (PK).Exploratory: Pharmacodynami